THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 199 PATIENT GROUPS with an interest in RARE DISEASES

Transcription

1 THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 199 PATIENT GROUPS with an interest in RARE DISEASES PUBLISHED MAY 2016

2 Dans notre domaine de maladies rares où des efforts ont été faits pour impliquer les patients. ( In our field of rare diseases, efforts have been made to involve patients. ) National France-based patient group specialising in rare neurological diseases in 2016, patientview is publishing 20 corporate reputation of pharma reports, analysing the results from the 1,075 patient groups responding to the 2015 survey. specialty reports: cancer I circulatory conditions I diabetes I hiv/aids I hepatitis I neurological conditions I mental health I respiratory conditions I skin conditions I rare diseases (10 reports) geographic-region reports: europe I eastern europe I germany I global I italy I latin america I nordic I spain I uk I usa (10 reports)

3 CONTENTS ABOUT THIS REPORT Page 1 WHAT DID RARE-DISEASE PATIENT GROUPS SAY ABOUT PHARMA IN 2015? Summary of the industry-wide findings (as judged by rare-disease patient groups) Page 3 A FEW COMMENTS ON THE RARE-DISEASE CORPORATE RANKINGS Page 6 WHAT CAN PHARMA COMPANIES DO TO IMPROVE THEIR CORPORATE REPUTATION? Page 7 COMMENTS FROM RARE-DISEASE PATIENT GROUPS, 2015 Page 8 METHODOLOGY OF THE PATIENT-GROUP SURVEY Page 12 APPENDIX 1: Data on how rare-disease patient groups see the pharmaceutical industry in 2015 Page 13 APPENDIX 2: Rankings of the 28 pharma companies for each of the 6 indicators of corporate reputation, as perceived by rare-disease patient groups in 2015 Page 18 APPENDIX 3: Profiles of the 28 companies Page 27 APPENDIX 4: Profiles of the 199 respondent rare-disease patient groups Page 57

4 LIST OF TABLES AND CHARTS BASED ON THE VIEWS OF RARE-DISEASE PATIENT GROUPS, 2015 Percentage of rare-disease patient groups claiming familiarity with the company Page 2 Percentage of rare-disease patient groups claiming familiarity with the company, and which also worked with it Page 2 Percentage of patient groups worldwide (by therapy area) stating that pharma is Excellent or Good at PROVIDING HIGH-QUALITY, USEFUL PRODUCTS Page 4 Percentage of patient groups worldwide (by therapy area) stating that pharma is Excellent or Good at PATIENT SAFETY Page 5 Top-ten pharma companies 2015, according to patient groups specialising in rare diseases (v. rare diseases ranking, 2014) Page 6 If a pharma company wishes to improve its corporate reputation with patients and patient groups, which single strategy from the list below do you think would be MOST IMPORTANT for the company to follow? Please select only ONE option Page 7 How do you think your organisation s members (or the people you represent) would rate the corporate reputation of the following healthcare sectors in 2015? Page 14 What do you think has happened to the corporate reputation of the pharma industry over the past five years? Page 15 How good or bad do you think the pharma industry is in 2015 at carrying out the following activities (all of which influence their corporate standing with patients and patient groups)? Page 16 How good or bad do you think the pharma industry is in 2015 at carrying out the following activities (all of which influence their corporate standing with patients and patient groups)? Page 17 Companies with the most effective PATIENT-CENTRED STRATEGY (rankings of 28 companies, 2015) Page 19 Companies providing the best HIGH-QUALITY PATIENT INFORMATION (rankings of 28 companies, 2015) Page 20 Companies with the best record on PATIENT SAFETY (rankings of 28 companies, 2015) Page 21 Companies with the most-useful HIGH-QUALITY PRODUCTS (rankings of 28 companies, 2015) Page 22 Companies with the best record of TRANSPARENCY (rankings of 28 companies, 2015) Page 23 Companies with the best record on INTEGRITY (rankings of 28 companies, 2015) Page 24 Rankings of the 28 pharmaceutical companies in 2015, alphabetic order Page 25 Rankings of the 28 pharmaceutical companies in 2015, highest to lowest Page 26 Geographic headquarters of 2015 s 199 respondent rare-disease patient groups by country Page 57 Geographic remit of 2015 s 199 respondent rare-disease patient groups Page 57

5 LIST OF TABLES AND CHARTS CONTINUED AbbVie page 29 Actavis page 30 Allergan page 31 Amgen page 32 AstraZeneca page 33 Baxalta page 34 Bayer page 35 Biogen Idec page 36 Boehringer Ingelheim page 37 B-MS page 38 Celgene page 39 Eli Lilly page 40 Gilead Sciences page 41 GSK page 42 Janssen page 43 Lundbeck page 44 Merck & Co (US) page 45 Merck KGaA page 46 Novartis page 47 Novo Nordisk page 48 Pfizer page 49 Roche page 50 Sandoz page 51 Sanofi page 52 Shire page 53 Takeda page 54 Teva page 55 UCB page 56 profiles of the 28 companies, according to the rare-disease patient groups familiar with these companies, or which have worked with them Each profile contains... company background information Annual revenue (latest-available year), comprising amount in currency, as quoted by the profiled company itself. = increase in revenue over the previous year or = decrease in revenue. The profiled company s main treatment subject areas (and areas of R&D). A mission statement from the profiled company. how the company has performed at six indicators of corporate reputation The profiled company s performance at the six indicators of corporate reputation in 2015, according to the rare-disease patient groups familiar with the company. The profiled company s performance at the six indicators of corporate reputation, according to the rare-disease patient groups that have worked with the company. How the profiled company performed among rare-disease patient groups for different countries/regions, compared with the company s global averages for rare-disease patient groups in how the company ranks for corporate reputation compared with other companies The profiled company s rankings among rare-disease patient groups in 2015 for the six indicators of corporate reputation, compared with 27 other companies. The profiled company s rankings worldwide in 2015 for the six indicators of corporate reputation, compared with 47 other companies. profile of the patient groups familiar with the company Other companies that partner with a significant number of the profiled company s partner patient groups. The countries of the patient groups familiar with the profiled company. Janssen Pharmaceutical Companies of Johnson & Johnson

6 Contact details PatientView Registered office: One Fleet Place, London, EC4M 7WS, UK Tel: +44-(0) Registered in England, number: Data protection registration number: Z VAT registration number: GB Copyright 2016 PatientView Ltd. All rights reserved. This booklet is the property of PatientView, and no part may be reproduced without permission, or passed on to any third party without the permission of PatientView.